Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Universität des Saarlandes | OTHER |
| Institut Paoli-Calmettes | OTHER |
| Medical University of Warsaw | OTHER |
| University Of Perugia |
Not provided
Not provided
Not provided
Not provided
Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.
The complex intervention in AlloLife will consist of a set of technically-supported tools that will enable active care management through the patient and treating physician to improve QoL.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention: | Experimental | Complex, technology supported survivorship intervention using wearable devices for patients, supportive patient apps and physician apps for risk prediction. Increased Cardio-oncology visits assigned to risk patients as predicted by the app. |
|
| Control arm: | No Intervention | Wearable device for patients together with a basic patient app providing feedback on the wearable device records and patient information material. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps | Combination Product | Patient-centered, technology-supported integrated survivorship- and care management |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life as measured by the FACT-BMT score | Change in QoL measured by the FACT BMT score on a continuous scale. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) as initially developed by McQuellon RP et al. BMT 1997. It scales between 0 (zero) and 196 on a continuous scale, where higher values refer to higher Quality of Life. | 12 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Norbert Graf, MD | Contact | +49- 6841/16-28397 | norbert.graf@uks.eu |
Not provided
Not provided
The IPD Sharing Plan will be developed during the project.
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Centre for Research and Technology Hellas | OTHER |
Not provided
Not provided
Not provided
Not provided